Vor Bio
Vor is pioneering autoimmune disease treatment by advancing a novel dual inhibitor, telitacicept, aiming to address diseases at their root causes. The company offers a collaborative and innovative environment focused on impactful scientific progress and growth.
Vor Bio is a clinical-stage cell and genome engineering company developing novel hematopoietic stem cell-based therapies for cancer. The company is focused on transforming the treatment of hematological malignancies through engineered stem cell transplantation and targeted therapeutics.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Vor Bio.
3% above the average for this role
Vor, with new CEO, changes course to target autoimmune disease
Jun 26, 2025
Director, Clinical Supply Chain (Clinical Supply), Late Stage
Jade Biosciences
Clinical Supply Chain Manager
PSI CRO
Associate Director of Clinical Supply Chain
IDEAYA Biosciences, Inc.
Sr. Clinical Supply Chain Manager
4D Molecular Therapeutics
Clinical Supply Chain Specialist
Janux Therapeutics
Senior Clinical Trial Drug Supply Manager
Amneal